Singapore moves to accelerate healthcare innovations in push to be regional clinical research hub
Among several moves, Singapore will establish a priority track assessing selected innovative health products, says Health Minister Ong Ye Kung.
Singapore is striving to become a top-tier clinical research hub in the region by accelerating healthcare innovations and streamlining regulatory processes, according to Health Minister Ong Ye Kung. The Health Sciences Authority (HSA) will introduce new initiatives to expedite drug development and trial regulations, including a priority track for selected health products to undergo simultaneous regulatory evaluation and health technology assessment.
Additionally, HSA will collaborate with the United Kingdom to establish a regulatory innovation corridor for breakthrough therapies, including those utilizing artificial intelligence (AI). By consolidating regulatory domains under HSA, the government aims to simplify the journey from research to clinical development, regulatory evaluation, and patient access, ultimately reducing approval times and uncertainties.
These efforts position Singapore as a trusted and efficient hub for clinical research, connecting with global markets and adhering to international standards.
Written by urgent.news from CNA - Singapore's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
